Last updated on May 2020

A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Gastro Esophageal Junction Cancer | Gastric Cancer
  • Age: Between 20 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Subject has histologically or cytologically confirmed diagnosis of gastric or gastro-esophageal junction adenocarcinoma.
  • Subject has gastric or gastroesophageal junction (GEJ) adenocarcinoma based on radiographic imaging or endoscopic examination.
  • Subject agrees not to participate in another interventional study while on treatment.
  • Subject has Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
  • Subject has predicted life expectancy 12 weeks.
  • Subject must have an available tumor specimen collected at any time prior to the first dose of study treatment.
  • Subject must meet all of the pre-specified criteria on the laboratory tests that will be analyzed locally within 7 days prior to the first dose of study drug.
  • Locally advanced or Metastatic gastric or GEJ adenocarcinoma with no standard of care treatment option or subject is ineligible to receive available standard of care treatment option.
  • Subject's tumor sample has Claudin (CLDN)18.2 membranous staining with any intensity as determined by central Immunohistochemistry (IHC) testing. (Safety part only)
  • Subject has CLDN18.2 high expression in 75% of tumor cells demonstrating moderate to strong membranous staining as determined by central IHC testing. (Expansion Part Only)
  • Subject is an appropriate candidate for a tumor biopsy and is amenable to undergo a tumor biopsy during the Screening period and on-treatment tumor biopsy. (Expansion Part Only)
  • Subject has at least 1 measurable lesion according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 within 28 days prior to the first dose of study treatment. For subjects with only 1 measurable lesion and prior radiotherapy, the lesion must be outside the field of prior radiotherapy or must have documented progression following radiation therapy. (Expansion Part Only)

Exclusion Criteria:

  • Subject has prior severe allergic reaction or intolerance to a monoclonal antibody, including humanized or chimeric antibodies.
  • Subject has had radiotherapy within 2 weeks prior to first dose of study drug. Subject who received palliative radiotherapy to peripheral bone metastases within 2 weeks prior to first dose of study drug and has recovered from all acute toxicities is allowed.
  • Subject has received other investigational agents or devices concurrently or within 4 weeks prior first dose of study drug.
  • Subject has received systemic immunosuppressive therapy, including systemic corticosteroids 2 weeks prior to first dose of study drug. Subjects using a physiologic replacement dose of hydrocortisone or its equivalent are allowed.
  • Subject has gastric outlet syndrome or persistent recurrent vomiting.
  • Subject has uncontrolled or significant gastrointestinal hemorrhage.
  • Subject has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
  • Subject has a known history of a positive test for human immunodeficiency virus (HIV) infection.
  • Subject has a positive test for hepatitis B surface antigen (HBsAg) or hepatitis C virus antibody (anti-HCV). Subjects who are negative for HBsAg, but hepatitis B core antibody (HBcAb) positive, hepatitis B virus deoxyribonucleic acid (DNA) test will be performed and if positive will be excluded. Subjects with positive serology but negative HCV ribonucleic acid (RNA) test results are eligible.
  • Subject has had within 6 months prior to first dose of study treatment any of the following: unstable angina, myocardial infarction, ventricular arrhythmia requiring intervention or hospitalization for heart failure
  • Subject has active infection requiring systemic therapy.
  • Subject has clinically significant other disease or co-morbidity, which may adversely affect the safe delivery of treatment within this trial.
  • Subject has psychiatric illness or social situations that would preclude study compliance.
  • Subject has active autoimmune disease that has required systemic immunosuppressive treatment in the past 2 years.
  • Subject has had a major surgical procedure within 28 days prior to the first dose of study drug.
  • Subject has Fridericia-corrected QT interval (QTcF) > 450 msec for males and > 470 msec for females on 12-lead electrocardiogram (ECG) at screening based on local testing.
  • Subject has any condition which makes the subject unsuitable for study participation.
  • Subject has another active malignancy which is likely to require treatment.
  • Subjects who find it difficult to adhere to the provisions of treatment and observation specified in the protocol.

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.